Molecular and Cellular Mechanisms of Antidepressant Action
The DOI matches its Crossref record; 88 of the 88 references it cites were found in a registry or an index.
Abstract
A long-standing theory is that brain monoamine signalling is critically involved in the mechanisms of antidepressant drug treatment. Theories on the nature of these mechanisms commenced with ideas developed in the 1960s that the drugs act simply by increasing monoamine availability in the synapse. However, this thinking has advanced remarkably in the last decade to concepts which position that antidepressant drug action on monoamine signalling is just the starting point for a complex sequence of neuroadaptive molecular and cellular changes that bring about the therapeutic effect. These changes include activation of one or more programmes of gene expression that leads to the strengthening of synaptic efficacy and connectivity, and even switching neural networks into a more immature developmental state. It is thought that through this increase in plasticity, key neural circuits within the limbic system are more easily remodelled by incoming emotionally relevant stimuli. This article attempts to bring together previous and current knowledge of antidepressant drug action on monoamine signalling at molecular and cellular levels, and introduces current thinking that these changes interact with neuropsychological processes ultimately to elevate mood.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Citations
Cites
Requirement of hippocampal neurogenesis for the behavioral effects of antidepressants
Santarelli, L., Saxe, M., Gross, C., Surget, A., Battaglia, F., Dulawa, S., Weisstaub, N., Lee, J., Duman, R., Arancio, O., et al. (2003) · Science · doi:10.1126/science.1083328 · Cited by 4,321 · cited 1×
“It is also proposed that increased production of newly formed neurones is one of the endpoints of the gene expression changes that are critical to the therapeutic effect of antidepressant treatment (Santarelli et al. 2003).”
THE CATECHOLAMINE HYPOTHESIS OF AFFECTIVE DISORDERS: A REVIEW OF SUPPORTING EVIDENCE
SCHILDKRAUT, J. J. (1965) · American Journal of Psychiatry · doi:10.1176/ajp.122.5.509 · Cited by 3,492
The molecular neurobiology of depression
Krishnan, V., & Nestler, E. J. (2008) · Nature · doi:10.1038/nature07455 · Cited by 2,889
A molecular and cellular theory of depression
Duman, R. S. (1997) · Archives of General Psychiatry · doi:10.1001/archpsyc.1997.01830190015002 · Cited by 2,129
Nibuya, M., Morinobu, S., & Duman, R. (1995) · The Journal of Neuroscience · doi:10.1523/jneurosci.15-11-07539.1995 · Cited by 2,109 · cited 1×
“Initial studies demonstrated that repeated antidepressant treatment to rodents increased expression of brain-derived neurotrophic factor (BDNF) (Lindefors et al. 1995; Nibuya et al. 1995).”
Sustained hippocampal chromatin regulation in a mouse model of depression and antidepressant action
Tsankova, N. M., Berton, O., Renthal, W., Kumar, A., Neve, R. L., & Nestler, E. J. (2006) · Nature Neuroscience · doi:10.1038/nn1659 · Cited by 1,780
The Biochemistry of Affective Disorders
Coppen, A. (1967) · British Journal of Psychiatry · doi:10.1192/bjp.113.504.1237 · Cited by 1,230
Current advances and trends in the treatment of depression
Blier, P., & de Montigny, C. (1994) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(94)90315-8 · Cited by 1,113
Delgado, P. L. (1990) · Archives of General Psychiatry · doi:10.1001/archpsyc.1990.01810170011002 · Cited by 924
The antidepressant fluoxetine restores plasticity in the adult visual cortex
Vetencourt, J. F. M., Sale, A., Viegi, A., Baroncelli, L., De Pasquale, R., F. O'Leary, O., Castrén, E., & Maffei, L. (2008) · Science · doi:10.1126/science.1150516 · Cited by 890
Ruhé, H. G., Mason, N. S., & Schene, A. H. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001949 · Cited by 861
Saarelainen, T., Hendolin, P., Lucas, G., Koponen, E., Sairanen, M., MacDonald, E., Agerman, K., Haapasalo, A., Nawa, H., Aloyz, R., et al. (2003) · The Journal of Neuroscience · doi:10.1523/jneurosci.23-01-00349.2003 · Cited by 800
The neurobiology of psychedelic drugs: implications for the treatment of mood disorders
Vollenweider, F. X., & Kometer, M. (2010) · Nature Reviews Neuroscience · doi:10.1038/nrn2884 · Cited by 723 · cited 1×
“Moreover, there are ongoing clinical trials into the antidepressant potential of psychedelic drug, psilocybin, reinforced by evidence that a 5-HT2 receptor agonist action may evoke changes in neural plasticity to produce long-lasting improvement in mood (Vollenweider and Kometer 2010).”
Duman, R. S., & Voleti, B. (2012) · Trends in Neurosciences · doi:10.1016/j.tins.2011.11.004 · Cited by 714
Artigas, F., Romero, L., de Montigny, C., & Blier, P. (1996) · Trends in Neurosciences · doi:10.1016/s0166-2236(96)10037-0 · Cited by 655
Antidepressant effect of optogenetic stimulation of the medial prefrontal cortex
Covington, H. E., Lobo, M. K., Maze, I., Vialou, V., Hyman, J. M., Zaman, S., LaPlant, Q., Mouzon, E., Ghose, S., Tamminga, C. A., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.1731-10.2010 · Cited by 621
Alterations in 5-HT 1B Receptor Function by p11 in Depression-Like States
Svenningsson, P., Chergui, K., Rachleff, I., Flajolet, M., Zhang, X., Yacoubi, M. E., Vaugeois, J.-M., Nomikos, G. G., & Greengard, P. (2006) · Science · doi:10.1126/science.1117571 · Cited by 572 · cited 1×
“Arc) (Pei et al. 2003; Svenningsson et al. 2006) and other transmitter signalling”
Castrén, E. (2005) · Nature Reviews Neuroscience · doi:10.1038/nrn1629 · Cited by 563
Harmer, C. J., Goodwin, G. M., & Cowen, P. J. (2009) · British Journal of Psychiatry · doi:10.1192/bjp.bp.108.051193 · Cited by 542 · cited 2×
“It is argued that this provides the basis for the relearning of new positive emotional associations eventually resulting in an improvement in subjective mood as new, positive, emotional contingencies are learned and experienced (Harmer et al. 2009).”
Meyer, J. H., Wilson, A. A., Sagrati, S., Hussey, D., Carella, A., Potter, W. Z., Ginovart, N., Spencer, E. P., Cheok, A., & Houle, S. (2004) · American Journal of Psychiatry · doi:10.1176/appi.ajp.161.5.826 · Cited by 517
cAMP Response Element-Mediated Gene Transcription Is Upregulated by Chronic Antidepressant Treatment
Thome, J., Sakai, N., Shin, K.-H., Steffen, C., Zhang, Y.-J., Impey, S., Storm, D., & Duman, R. S. (2000) · The Journal of Neuroscience · doi:10.1523/jneurosci.20-11-04030.2000 · Cited by 508
5-HT1A autoreceptor levels determine vulnerability to stress and response to antidepressants
Richardson-Jones, J. W., Craige, C. P., Guiard, B. P., Stephen, A., Metzger, K. L., Kung, H. F., Gardier, A. M., Dranovsky, A., David, D. J., Beck, S. G., et al. (2010) · Neuron · doi:10.1016/j.neuron.2009.12.003 · Cited by 450
A negative regulator of MAP kinase causes depressive behavior
Duric, V., Banasr, M., Licznerski, P., Schmidt, H. D., Stockmeier, C. A., Simen, A. A., Newton, S. S., & Duman, R. S. (2010) · Nature Medicine · doi:10.1038/nm.2219 · Cited by 412
Fear erasure in mice requires synergy between antidepressant drugs and extinction training
Karpova, N. N., Pickenhagen, A., Lindholm, J., Tiraboschi, E., Kulesskaya, N., Ágústsdóttir, A., Antila, H., Popova, D., Akamine, Y., Sullivan, R., et al. (2011) · Science · doi:10.1126/science.1214592 · Cited by 382
The Role of CREB in Depression and Antidepressant Treatment
Blendy, J. A. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2005.11.003 · Cited by 365
Serotonin4 (5-HT4) Receptor Agonists Are Putative Antidepressants with a Rapid Onset of Action
Lucas, G., Rymar, V. V., Du, J., Mnie-Filali, O., Bisgaard, C., Manta, S., Lambas-Senas, L., Wiborg, O., Haddjeri, N., Piñeyro, G., et al. (2007) · Neuron · doi:10.1016/j.neuron.2007.07.041 · Cited by 359
Conti, A. C., Cryan, J. F., Dalvi, A., Lucki, I., & Blendy, J. A. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-08-03262.2002 · Cited by 328
Gartside, S. E., Umbers, V., Hajós, M., & Sharp, T. (1995) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.1995.tb15919.x · Cited by 312
Self-citationEvaluation of Antidepressant-related Behavioral Responses in Mice Lacking the Serotonin Transporter
Holmes, A. (2002) · Neuropsychopharmacology · doi:10.1016/s0893-133x(02)00374-3 · Cited by 286
Marek, G. J., Carpenter, L. L., McDougle, C. J., & Price, L. H. (2003) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300057 · Cited by 275 · cited 1×
“Moreover, there are both preclinical and clinical data suggesting that 5-HT2 receptor antagonists have SSRI augmenting properties (Marek et al. 2003), and this might link to blockade of 5-HT2 receptor feedback mechanisms.”
Neuropharmacology of Serotonin
(1989) · European Journal of Pharmacology · doi:10.1016/0014-2999(89)90276-8 · Cited by 267
Cryan, J. F., O'Leary, O. F., Jin, S.-H., Friedland, J. C., Ouyang, M., Hirsch, B. R., Page, M. E., Dalvi, A., Thomas, S. A., & Lucki, I. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0401080101 · Cited by 252
Serotonin and emotional processing: does it help explain antidepressant drug action?
Harmer, C. J. (2008) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.06.036 · Cited by 219
Reversal of hippocampal neuronal maturation by serotonergic antidepressants
Kobayashi, K., Ikeda, Y., Sakai, A., Yamasaki, N., Haneda, E., Miyakawa, T., & Suzuki, H. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0912690107 · Cited by 212
Mayorga, A. J., Dalvi, A., Page, M. E., Zimov-Levinson, S., Hen, R., & Lucki, I. (2001) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/s0022-3565(24)29479-9 · Cited by 209
Conti, B., Maier, R., Barr, A. M., Morale, M. C., Lu, X., Sanna, P. P., Bilbe, G., Hoyer, D., & Bartfai, T. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4001897 · Cited by 204
Cell atrophy and loss in depression: reversal by antidepressant treatment
Banasr, M., Dwyer, J. M., & Duman, R. S. (2011) · Current Opinion in Cell Biology · doi:10.1016/j.ceb.2011.09.002 · Cited by 201
Millan, M. J. (2009) · Neurotherapeutics · doi:10.1016/j.nurt.2008.10.039 · Cited by 196
Important messages in the ‘post’: recent discoveries in 5-HT neurone feedback control
Sharp, T., Boothman, L., Raley, J., & Quérée, P. (2007) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2007.10.009 · Cited by 190
Self-citationKetamine as a Novel Antidepressant: From Synapse to Behavior
Murrough, J. W. (2012) · Clinical Pharmacology & Therapeutics · doi:10.1038/clpt.2011.244 · Cited by 172 · cited 1×
“(Duman and Voleti 2012; Murrough 2012).”
Antidepressant Effects of Fibroblast Growth Factor-2 in Behavioral and Cellular Models of Depression
Elsayed, M., Banasr, M., Duric, V., Fournier, N. M., Licznerski, P., & Duman, R. S. (2012) · Biological Psychiatry · doi:10.1016/j.biopsych.2012.03.003 · Cited by 169
Hayward, G., Goodwin, G. M., Cowen, P. J., & Harmer, C. J. (2005) · Biological Psychiatry · doi:10.1016/j.biopsych.2004.11.016 · Cited by 162 · cited 1×
“For example, tryptophan depletion caused negative biases in the recognition of facial expressions in recovered depressed patients (Hayward et al. 2005), whereas SSRI treatment had the opposite effect (Harmer 2008), with both effects occurring independent of changes in mood.”
Biochemical and Behavioral Evidence for Antidepressant-Like Effects of 5-HT6Receptor Stimulation
Svenningsson, P., Tzavara, E. T., Qi, H., Carruthers, R., Witkin, J. M., Nomikos, G. G., & Greengard, P. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.3110-06.2007 · Cited by 160
VEGF as a potential target for therapeutic intervention in depression
Warner‐Schmidt, J. L., & Duman, R. S. (2007) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2007.10.013 · Cited by 159
Melas, P. A., Rogdaki, M., Lennartsson, A., Björk, K., Qi, H., Witasp, A., Werme, M., Wegener, G., Mathé, A. A., Svenningsson, P., et al. (2012) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000940 · Cited by 157
5-HT and depression: is the glass half-full?
Sharp, T., & Cowen, P. J. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.02.003 · Cited by 153
Self-citationEpigenetic regulation of BDNF expression according to antidepressant response
Lopez, J. P., Mamdani, F., Labonte, B., Beaulieu, M.-M., Yang, J. P., Berlim, M. T., Ernst, C., & Turecki, G. (2013) · Molecular Psychiatry · doi:10.1038/mp.2012.38 · Cited by 146
Greene, J., Banasr, M., Lee, B., Warner-Schmidt, J., & Duman, R. S. (2009) · Neuropsychopharmacology · doi:10.1038/npp.2009.68 · Cited by 143
Increased Vulnerability to Depressive-Like Behavior of Mice with Decreased Expression of VGLUT1
Garcia‐García, Á. L., Elizalde, N., Matrov, D., Harro, J., Wojcik, S. M., Venzala, E., Ramírez, M. J., Río, J. D., & Tordera, R. M. (2009) · Biological Psychiatry · doi:10.1016/j.biopsych.2009.02.027 · Cited by 143
Riad, M. (2004) · Journal of Neuroscience · doi:10.1523/jneurosci.0950-04.2004 · Cited by 141
Homers regulate drug-induced neuroplasticity: Implications for addiction
Szumlinski, K. K., Ary, A. W., & Lominac, K. D. (2007) · Biochemical Pharmacology · doi:10.1016/j.bcp.2007.07.031 · Cited by 137
Gelenberg, A. J., & Chesen, C. L. (2000) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v61n1002 · Cited by 127
Identification of the Cortical Neurons that Mediate Antidepressant Responses
Schmidt, E. F., Warner-Schmidt, J. L., Otopalik, B. G., Pickett, S. B., Greengard, P., & Heintz, N. (2012) · Cell · doi:10.1016/j.cell.2012.03.038 · Cited by 125
Distinct Roles for Different Homer1 Isoforms in Behaviors and Associated Prefrontal Cortex Function
Lominac, K. D., Oleson, E. B., Pava, M., Klugmann, M., Schwarz, M. K., Seeburg, P. H., During, M. J., Worley, P. F., Kalivas, P. W., & Szumlinski, K. K. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.3764-05.2005 · Cited by 118
Wnt2 Expression and Signaling Is Increased by Different Classes of Antidepressant Treatments
Okamoto, H., Voleti, B., Banasr, M., Sarhan, M., Duric, V., Girgenti, M. J., DiLeone, R. J., Newton, S. S., & Duman, R. S. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.04.023 · Cited by 116
Cour, C. M. L., Boni, C., Hanoun, N., Lesch, K.-P., Hamon, M., & Lanfumey, L. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-06-02178.2001 · Cited by 113
Lindholm, J., Autio, H., Vesa, L., Antila, H., Lindemann, L., Hoener, M. C., Skolnick, P., Rantamäki, T., & Ċastrén, E. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.08.015 · Cited by 112
Ren‐Patterson, R. F., Cochran, L. W., Holmes, A., Lesch, K., Lu, B., & Murphy, D. L. (2006) · Cellular and Molecular Neurobiology · doi:10.1007/s10571-006-9048-6 · Cited by 101
Neurogenic Effects of Fluoxetine Are Attenuated in p11 (S100A10) Knockout Mice
Egeland, M., Warner-Schmidt, J., Greengard, P., & Svenningsson, P. (2010) · Biological Psychiatry · doi:10.1016/j.biopsych.2010.01.024 · Cited by 94
Sillaber, I., Panhuysen, M., Henniger, M. S. H., Ohl, F., Kühne, C., Pütz, B., Pohl, T., Deussing, J. M., Paez-Pereda, M., & Holsboer, F. (2008) · Psychopharmacology · doi:10.1007/s00213-008-1232-6 · Cited by 93
Yanpallewar, S. U., Fernandes, K., Marathe, S. V., Vadodaria, K. C., Jhaveri, D., Rommelfanger, K., Ladiwala, U., Jha, S., Muthig, V., Hein, L., et al. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.2309-09.2010 · Cited by 91
Lindefors, N., Brodin, E., & METSIS, M. L. (1995) · Neuroscience · doi:10.1016/0306-4522(94)00550-o · Cited by 86
Antidepressant drug treatment induces Arc gene expression in the rat brain
Pei, Q., Zetterström, T., Sprakes, M., Tordera, R. M., & Sharp, T. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00504-9 · Cited by 82
Self-citationAddition of the α2-Antagonist Yohimbine to Fluoxetine: Effects on Rate of Antidepressant Response
Sanacora, G., Berman, R., Cappiello, A., Oren, D. A., Kugaya, A., Liu, N., Gueorguieva, R. V., Fasula, D., & Charney, D. S. (2004) · Neuropsychopharmacology · doi:10.1038/sj.npp.1300418 · Cited by 79
Elizalde, N., Pastor, P. M., Garcia‐García, Á. L., Serres, F., Venzala, E., Huarte, J., Ramírez, M. J., Del Rio, J., Sharp, T., & Tordera, R. M. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06854.x · Cited by 77
Self-citationEpigenetics, Depression and Antidepressant Treatment
Menke, A., Klengel, T., & B. Binder, E. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212803523590 · Cited by 77
Rabiner, E. A. (2000) · Neuropsychopharmacology · doi:10.1016/s0893-133x(00)00109-3 · Cited by 75
Calabrese, F., Molteni, R., Gabriel, C., Mocaër, E., Racagni, G., & Riva, M. A. (2010) · Psychopharmacology · doi:10.1007/s00213-010-2129-8 · Cited by 69
Whale, R., Terao, T., Cowen, P., Freemantle, N., & Geddes, J. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881108097714 · Cited by 68
Portella, M. J., de Diego-Adeliño, J., Ballesteros, J., Puigdemont, D., Oller, S., Santos, B., Álvarez, E., Artigas, F., & Pérez, V. (2011) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05827blu · Cited by 63
Tordera, R. M., Pei, Q., & Sharp, T. (2005) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2005.03192.x · Cited by 61
Self-citationQuérée, P., Peters, S., & Sharp, T. (2009) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2009.00406.x · Cited by 56
Self-citationFarley, S., Dumas, S., Mestikawy, S. E., & Giros, B. (2011) · Neuropharmacology · doi:10.1016/j.neuropharm.2011.09.010 · Cited by 56
Mongeau, R., Martin, C. B. P., Chevarin, C., Maldonado, R., Hamon, M., Robledo, P., & Lanfumey, L. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06932.x · Cited by 51
Larsen, M. H., Rosenbrock, H., Sams‐Dodd, F., & Mikkelsen, J. D. (2006) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2006.10.029 · Cited by 47
Scorza, M., Lladó‐Pelfort, L., Oller, S., Cortés, R., Puigdemont, D., Portella, M., Pérez‐Egea, R., Alvarez, E., Celada, P., Pérez, V, et al. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01770.x · Cited by 46
Studying synaptic plasticity in the human brain and opportunities for drug discovery
Nathan, P. J., Cobb, S., Lu, B., Bullmore, E. T., & Davies, C. H. (2011) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2011.06.008 · Cited by 44
Castro, E., Harrison, P. J., Pazos, Á., & Sharp, T. (2000) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2000.0750755.x · Cited by 42
Self-citationEarly induction of CREB activation and CREB-regulating signalling by antidepressants
Tardito, D., Musazzi, L., Tiraboschi, E., Mallei, A., Racagni, G., & Popoli, M. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709000376 · Cited by 42
Stahl, S. M., & Palazidou, L. (1986) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(86)90384-6 · Cited by 40
Castro, E., Tordera, R. M., Hughes, Z. A., Pei, Q., & Sharp, T. (2003) · Journal of Neurochemistry · doi:10.1046/j.1471-4159.2003.01782.x · Cited by 34
Self-citationHughes, Z. A., Starr, K. R., Scott, C. M., Newson, M. J. F., Sharp, T., Watson, J. M., Hagan, J. J., & Dawson, L. A. (2007) · Psychopharmacology · doi:10.1007/s00213-006-0691-x · Cited by 29
Self-citationYohimbine augmentation of fluvoxamine in refractory depression: A single-blind study
Cappiello, A., McDougle, C. J., Malison, R. T., Heninger, G. R., & Price, L. H. (1995) · Biological Psychiatry · doi:10.1016/0006-3223(95)00367-3 · Cited by 28
Catecholamine and 5-HT ex vivo as an index of in-vivo neuronal activity and regulation
Broadhurst, A. M., & Briley, M. (1988) · Trends in Pharmacological Sciences · doi:10.1016/0165-6147(88)90249-0 · Cited by 18
Kolasa, M., Kuśmider, M., Solich, J., Faron‐Górecka, A., Krawczyk, M. J., KUŁAKOWSKI, K., & Dziedzicka‐Wasylewska, M. (2012) · Psychopharmacology · doi:10.1007/s00213-012-2714-0 · Cited by 17
Serres, F., Millan, M. J., & Sharp, T. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000733 · Cited by 17
Self-citationNew antidepressant drugs: Is there anything new they tell us about depression?
Tyrer, P. J., & Marsden, C. A. (1985) · Trends in Neurosciences · doi:10.1016/0166-2236(85)90151-1 · Cited by 8
Cowen, P. J., & Harmer, C. J. (2009) · Oxford University Press eBooks · doi:10.1093/med/9780199533077.003.0013 · Cited by 6
Cited by
Malhi, G. S., & Mann, J. J. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31948-2 · Cited by 4,099
Otte, C., Gold, S. M., Penninx, B. W., Pariante, C. M., Etkin, A., Fava, M., Mohr, D. C., & Schatzberg, A. F. (2016) · Nature Reviews Disease Primers · doi:10.1038/nrdp.2016.65 · Cited by 2,269
Emerging mechanisms and treatments for depression beyond SSRIs and SNRIs
Dale, E., Bang-Andersen, B., & Sánchez, C. (2015) · Biochemical Pharmacology · doi:10.1016/j.bcp.2015.03.011 · Cited by 234
Trambaiolli, L. R., Kohl, S. H., Linden, D. E. J., & Mehler, D. M. A. (2021) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2021.02.015 · Cited by 87
Mexican medicinal plants with anxiolytic or antidepressant activity: Focus on preclinical research
López‐Rubalcava, C., & Estrada-Camarena, E. M. (2016) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2016.03.053 · Cited by 71
Metadata
- Authors
- Sharp, T.
- Affiliations
- University of Oxford (GB)
- Corresponding author
- Sharp, Trevor
- ORCID
- Sharp, Trevor
- Venue
- Current Topics in Behavioral Neurosciences
- Publisher
- Springer Berlin Heidelberg
- Published
- 2012
- Volume
- 14
- Pages
- 309-325
- ISSN
- 1866-3370 (ISSN-L)
- 1866-3389
- OpenAlex
- W1490282579
- Semantic Scholar
- 0e603e834835e77a93a98b41744375d1dd843771
- Cited by
- 36
- References
- 88
- Citations by year
- 2026: 1 · 2025: 4 · 2024: 5 · 2023: 5 · 2022: 6 · 2021: 2 · 2020: 4 · 2019: 2 · 2018: 1 · 2016: 3 · 2015: 1 · 2014: 2
- FWCI
- 2.93
- Type
- book chapter
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- Current topics in behavioral neurosciences (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neurotransmitter Receptor Influence on Behavior
- Life Sciences › Neuroscience › Cellular and Molecular Neuroscience › Neuroscience and Neuropharmacology Research
- Keywords
- antidepressant mechanism, synaptic plasticity, neural adaptation, gene expression, synaptic efficacy, neural network development, limbic system, mood regulation, emotional stimuli, neuropsychology
- MeSH terms
- Animals, Antidepressive Agents, Brain, Humans, Neuronal Plasticity, Neurons, Signal Transduction
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.